2024 M&A Year in Review - Flipbook - Page 36
36
We advised Daiichi Sankyo on a global collaboration
to develop and commercialize three of its DXd antibodydrug conjugate (ADC) candidates, patritumab deruxtecan
(HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug
deruxtecan (R-DXd).
The collaboration, valued at US $22 billion, builds on
Daiichi Sankyo’s commitment to develop novel medicines
for patients with cancer.
Lawyers in our Northern Virginia office led the
transaction, with support from our New York, Tokyo,
and Washington, D.C. offices and our antitrust,
intellectual property, regulatory, and tax practices.
Merck
known as MSD outside of the United States and Canada
We advised Merck, a global biopharmaceutical company
known as MSD outside of the United States and Canada,
on its acquisition of CN201, a novel autoimmune
treatment drug.
Merck plans to evaluate CN201 as a treatment for B-cell
malignancies and to investigate its potential to provide a novel,
scalable option for the treatment of autoimmune diseases.
Lawyers in our Washington, D.C. and Baltimore offices
led the transaction, with support from our Beijing, Denver,
Hong Kong, London, Los Angeles, New York, Northern
Virginia, and Shanghai offices and our employee benefits,
employment, intellectual property, international trade,
privacy and cybersecurity, real estate, regulatory, and
tax practices.
